Screener
Vor Biopharma VOR Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by Vor Biopharma in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The source filing: Vor Biopharma’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 8:31 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-220689
| (in thousands, except share and per share amounts) | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Other income (expense): | ||
| Interest income | 3,935 | 805 |
| Change in fair value of warrant liabilities | (188,360) | — |
| Total other (expense) income | (184,425) | 805 |
| Net loss | $(219,585) | $(32,486) |
| Net loss per share attributable to common stockholders, basic and diluted(1) | $(5.11) | $(5.21) |
| Weighted-average common shares outstanding, basic and diluted(1) | 43,011,544 | 6,241,207 |
| Other comprehensive income (loss): |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Vor Biopharma's other income (expense)?
- Vor Biopharma (VOR) reported other income (expense) of -$184.43M in Q1 2026.
- How has Vor Biopharma's other income (expense) changed year-over-year?
- Vor Biopharma's other income (expense) decreased by 23009.9% year-over-year, from $805K to -$184.43M.
- What is the long-term trend for Vor Biopharma's other income (expense)?
- Over 3 years (2021 to 2024), Vor Biopharma's other income (expense) has grown at a 229.9% compound annual growth rate (CAGR), from $119K to $4.27M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.
Ask your AI about Vor Biopharma's other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude